Remedy Plan
Manufacturing · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
12111 Parklawn Dr Rm 120, Rockville, Mar...Website
www.remedyplan.comRevenue
<$5 MillionIndustry
About Remedy Plan
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedys groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. The company is advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.Explore more
Remedy Plan Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Remedy Plan
Compare insights from companies similar to Remedy Plan, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Remedy Plan Tech Stack
A closer look at the technologies used by Remedy Plan
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Remedy Plan
Sign Up For FreeTo access detailed company insights
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedys groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities... Read More
